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Abstract.introduction.and.importance: Autosomal dominant hypophosphatemic rickets is the most common form of
rare rickets, commonly manifests in children but sometimes the condition remains undiagnosed due to lack of
knowledge &/or awareness of treating physicians or surgeons.
Case presentation: We describe a case of 43 years old female with multiple fragility fractures since childhood,
corrected surgically but never investigated. She had stunted growth, bowing deformities and loss of teeth.
Clinical discussion: A detailed history and examination along with metabolic and genetic work up mounted the
diagnosis of X linked hypophosphatemic osteomalacia. The pathophysiology involves the mutation or the loss of
the phosphate regulating gene on PHEX, that causes reduced mineralization of bones and teeth.
Conclusion: Diagnostic delay in this patient resulted in increased disabilities affecting her mobility and lif estyle.

1. Introduction

We describe a case presenting as adult with multiple bone de
formities from childhood and treated surgically without diagnosis.This
work is inline with the SCARE criteria 2020 [3,4]. (ref:scare criteria
2020)

Inherited metabolic diseases (IMDs) of bone are rare, with less than 1
per 200,000 incidence. Not only they have a heterogenous etiology,
there is a wide variation in onset and disease severity [1]. Recently
significant advances are made in understanding the underlying genetic
and molecular pathways in the pathogenesis of rare bone diseases with
new gene discovery and expansion of the classification system [1].
Almost 400 different forms of skeletal dysplasias have been described so
far and the number continues to increase with advancement in molec
ular pathology. Worldwide the diagnostic capability and provision of
accurate genetic counseling has been greatly improved. Increase
comprehension of molecular pathways has also resulted in increase
availability of therapeutic options for management of many disorders
like osteogenesis imperfecta (OI), X-linked hypophosphatemia (XLH),
primary hypoparathyroidism, osteopetrosis and hypophosphatasia.
There is evolving interest in gene manipulation therapy too, to provide
curative options for these often lethal disorders [2]. However, knowl
edge and awareness of these disorders among clinicians remains a
diagnostic challenge because of their rarity and wide variety. But once
diagnosed accurately patients may be treated appropriately, bone ab
normalities prevented, emotional and financial devastation of the pa
tients and their families may be compensated to some extent.

1.1. Case presentation
A forty three years old, wheelchair-bound female presented to the
metabolic bone clinic of Aga Khan University Hospital with short stature
and grossly deformed bones of limbs and vertebrae. She achieved all
milestones on time in childhood. She belonged to a financially sound
family. The patient successfully passed her middle school and could not
continue further studies because of her illness. There was no family
history of having similar disorder and all of her siblings were in good
state of health.
She developed low trauma fracture for the first time at eight years of
age and was treated surgically. She had multiple low trauma fractures
since childhood and surgical corrections with placement of rods were
performed on multiple occasions. Her disability continued to increase
with time and she was unable to walk and became wheelchair-bound.
She lost all her teeth and was wearing dental prosthesis when exam
ined in clinic. She also had a history of low trauma hip fracture one year
back. She developed hypertension at the age of forty one years for which
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she was taking the combination of valsartan/hydrochlorothiazide 160/
25mg.
On examination, the patient was short in height 4ft, with extreme
bowing deformities involving leg, arms and back. She has light blue
sclera, artificial teeth with clear oral hygiene. She had multiple scars of
previous surgeries on arms and legs.
Results of the few biochemical investigations available with the pa
tient included a normal complete blood count and lipid profile, serum
calcium of 9.4 mg/dl, a serum 25 hydroxy vitamin D (25OHD) of 21.9
ng/ml, blood urea nitrogen and creatinine of 16 mg/dl and 0.8 mg/dl
respectively. She was prescribed calcium supplements, and injection
zoledronic acid. On her inquiry from physician, she was told that she had
low bone mineral density (BMD) on DXA and was also provided with the
diagnosis of Osteogenesis imperfecta few years back.
We advised for a complete metabolic workup. Her biochemical
investigation showed serum calcium 9.1 mg/dl (while on calcium sup
plement), serum phosphorus 2.2 mg/dl, serum 25OHD 27 ng/dl,1,25
(OH)D 54pg/dl, iPTH 176pg/dl. 24 hours urinary chemistry showed the
following: protein 78.4 mg/dl, phosphorus 275.5, potassium 18.26, so
dium 69.49, creatinine 0.34mmol/24hrs and creatinine clearance
73.7ml/min. The patient was identified to have low phosphorus and
high PTH with optimal vitamin D levels. A preliminary diagnosis of
hypophosphatemic osteomalacia was made and genetic consult was
sought. Sample for genetic testing of the following hypophosphatemic
gene panel ALPL, CLCNS, CYP2787, CYP2R1, DMPI, ENPPI, FAH,
FAM20C, FGF23, FGFR1, PHEX, SLC34A3, VDR was sent to Invitae
Medical Genetic Testing Expert Trust in Sanfransisco California. A
pathogenic variant c.871C > T ((p. Arg291) was identified on PHEX
gene confirming the diagnosis of X linked hypophosphatemic rickets.
She was started with potassium phosphate in divided doses and
alfacalcidiol once daily. She has been counseled for XLH in detail about
the disease and its inheritance, she was provided with instructions to
avoid fall. On follow up after four weeks time, her pain greatly improved
and she was advised to repeat serum calcium, serum phosphate and
plasma PTH.

common hereditary forms of rickets and osteomalacia in western
countries [7]. Renal hypophosphatemia can be calculated by measuring
the tubular maximum for phosphate reabsorption (TMP/GFR) by
routine biochemical investigations[8]. Reduced TMP/GFR with low
serum phosphorus points is suggestive of renal phosphate wasting. In
addition low or normal alkaline phosphatase, normal parathyroid levels
and normal or reduced calcium levels would further support hypo
phosphatemic rickets/osteomalacia. Table 1 shows the types of hypo
phosphatemic rickets/osteomalacia encountered in clinical practice
with distinct pathophysiological basis, gene affected and different ap
proaches to treatment with subtle difference in the biochemical diag
nosis by routine chemistries. Hence, genetic testing plays an important
role in differentiating amongst the inherited hypophosphatemic condi
tions. With increase availability of therapeutic options; it is important to
differentiate between the various hypophosphatemic conditions [9]. For
example ADHR/O has similar manifestations, with clinical rickets, and
inappropriately low levels of 1,25 (OH)2 D. The cause is mutations of
FGF23 gene that result in resistance to degradation, and accumulation of
high circulating levels of FGF23, and subsequent phosphaturia. The
spectrum of disease in ADHR/O includes not only the classic presenta
tion with early onset of hypophosphatemia and rickets, but also includes
delayed onset of clinically evident disease [9]. in which patients present
after puberty with hypophosphatemia at an age ranging from 14.5 to 45
years with complaints of bone pains, weakness and fatigue without
having histories of rickets or lower extremity deformities as a child.
Econs in 1997 suggested that apparently individuals who presented as
adults were able to compensate for genetic defects initially but later lost
the ability to compensate [10]. Treatment involves correction of ab
normalities caand administration of calcitriol and phosphate. However,
there is limited data on treatment of ADHR/O compare to XLH. Simi
larly, in HHRH, the accurate diagnosis has important therapeutic im
plications. Unlike XLH & ADHR/O, phosphate supplementation alone
can bring in remission wheras addition of vitamin D can create com
plications such as hypercalcemia, nephrocalcinosis and renal damage.
XLH is rare but commonest among other inherited forms of rickets.
Most commonly occurs in children (1 in 20,000) but often misdiagnosed
in childhood and may manifest as osteomalacia in adults [7]. The
pathophysiology involves the loss of phosphate regulating gene with the
homology to endopeptidase located on the X chromosome (PHEX) [11,
12]. PHEX enzymes are involved in phosphate homeostasis through
regulation of a protein called Fibroblasr growth factor (FGF23), secretd
by bone osteoclasts and osteoblasts [11]. FGF 23 activates the renal
KLOTHO receptors 1 that inhibit the phosphate reabsorption by down
regulation of Napi2a and Napi2c expressions and sodium-phosphate
co-transporter in the proximal renal tubules resulting in hypo
phosphatemia. FGF23 can reduce the regulation of CYP271B (that en
codes 25OHD-1@-Hydroxylase) and upgrade the control of CYP24A1
(that encode 24-Hydroxylase) [13]. As a result there is lower level of 1,
25OH2D due to decreased synthesis and increased catabolism. FGF23 is
involved in several phosphate wasting disorders including Autosomal
dominant hypophosphatemic rickets/osteomalacia (ADHR/O), onco
genic hypophosphatemic osteomalacia (OHO), McCune-Albright syn
drome (MAS), fibrous dysplasia of bone (FD), and humoral
hypercalemia of malignancy [9].
In Pakistan the first case of hypophosphatemic rickets was reported
in 2004 diagnosis were made on the basis of family history and lab in
vestigations. Now we report the second case of XLH, confirmed on ge
netic testing.This case report provides a new doorway to the
investigations for physicians/clinicians. It is a possibility that there is
underreporting of such cases. In the past this patient was given the
diagnosis of osteogenesis imperfecta which is associated with type 1
collagen deficiency. While fragility fractures are common in both, the
biochemical investigations are within normal limits in OI in contrast to
XLH. Hence, it is important to screen with appropriate lab investigation.
Patient was councelled regarding the XLRH and prescribed with calcium
phospahtes and vitamin D supplements.

2. Discussion
The diagnosis of many rare bone diseases has been limited by
physician access to the most up-to-date information about availability of
diagnostic tests and diagnostic criteria for these rare diseases. A variety
of factors including lack of knowledge and/or experience, lack of re
sources, or failure to follow recommendations may interfere with a
physician’s use of effective diagnostic techniques, preventive measures,
and timely managements. Although genetic tests are crucial to the
diagnosis of many rare bone diseases [5] the ordering of a specific test or
set of tests typically depends on a clinician’s evaluation and ability to
recognize clues pointing to conditions for which genetic testing may be
warranted. However, availability of genetic testing in Pakistan is only
available at few places, but the initial stages of diagnosis still depend on
classic clinical practices including patient history, physical examination,
use of laboratory investigations and application of clinical knowledge
and reasoning skills. One dilemma for clinicians and patients is that
many rare diseases have symptoms that accompany a number of com
mon conditions and laboratory results may or may not be definitive.
Physicians may consider common conditions that are consistent with the
available information before considering rare conditions.
Rickets and osteomalacia represents a group of diseases of divergent
causes, characterized by a defect in matrix mineralization [6]. The cause
is any condition resulting in inadequate calcium or phosphate miner
alization of bone osteoid resulting in either hypocalcemia or hypo
phosphatemia. Phosphate being sufficiently abundant in natural foods
dietary phosphate deficiency is unlikely to develop except under con
ditions of extreme starvation. Phosphate homeostasis and plasma
phosphate concentration depends primarily on the renal tubular trans
port of phosphate and disorders of renal phosphate wasting are the most
245
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Table 1
CLINICAL biochemical, molecular and treatment in different hypophosphatemic rickets/osteomalacia.

BLOODS

URINE

246
CLINICAL
PRESENTATION

MOLECULAR
PATHWAYS

X-Linked hypophosphatemic
osteomalacia (XLH)

Autosomal hypophosphatemic
osteomalacia (ADHO)

Vitamin d resistent hypophosphatemic
osteomalacia

Mc Cune albright syndrome (MAS)

Fibrodysplasia ossificans
progressiva (FOP)

S. CALCIUM
S. PHOSPHATE
Alkaline
phosphatase
25 OHD
1,25 (OH)D
PTH
URINARY
CALCIUM
URINARY
PHOSPHATE
TMP/GFR
AGE OF
PRESENTATION
BONE
DEFORMITIES

Normal
Decreased
Increased/Normal

Normal
Decreased
Increased

Decreased
Decreased
Increased

Normal/Increased
Decreased
Increased

Normal
Decreased
Increased

Normal
Normal/Decreased
Normal/Increased
Normal

Normal
Normal/Decreased
Normal/Increased
Normal

Normal
Normal
Increased
Increased

Normal
Normal
Increased
Normal

Normal
Normal
Increased
Normal

Increased

Increased

Increased

Increased

Increased

Decreased
7–8 years

Decreased
5–7 years
14.5–45 years
Bone pain
Fatigue
Muscle weakness fractures

Decreased
6–7 years

Decreased
15 -20 YARS

Decreased
13–20s

Leg bone deformities, Cranial deformities,
frontal bossing.

Bone pain, Heterotopic ossification
of soft tissues, immobility, swelling
of femur, tibia, ribs and skull

DENTAL
DEFORMITIES

Dental carries, Tooth
deformities
PHEX Mutation on 22.2 and
22.1 on X chromosome

Tooth access

Delayed tooth eruption

Heterozygous Point mutation
on amino acid 176 or 179 at
FGF23

Genetic defect in conversion of 25
hydroxyvitaminD2 to 1,25 dihydroxy
vitamin D and increased levels of FGF 23.

Vitamin D supplements, oral
phosphate supplements,
Burosumab

Oral Phosphate supplements
and calcitriol

Oral phosphate and calcitriol
supplements

Not apparent bony deformities.
CAFÉ-‘aulet spots, Mosaic like skin
pigmentation
Endocrinopathies.
Swelling of the jaws. Fibrous lesion of
the jaws
Embryonic postzygotic activation in
GNAS 1 gene encoding cAMP
pathways associated G protein and
Gas.
Bisphosphonates, Strengthening
exercises, Surgical interventions.

Short stature, bowing of legs,
Multiple fracture history,
cranial bossing

Mutation on ACVR1/ALK2 gene on
chromosome 2q 24
Glucocorticoids to avoid the
infections, surgical intervention
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MAIN MODE OF
TREATMENT
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One relatively newer drug option is that of Cinacalcet; which is a
calcimimmatics and regulates the parathyroid hormone by decreasing
the extracellular calcium and reducing the parathyroid levels[14].
Recently, Burosumab (Crysvita, Ultragenyx) has been approved by FDA
for the treatment of hypophosphatemic rickets and recommended as the
first line of treatment for the adults and children older then 1 year
suffering from hypophosphatemic rickets. Burosumab is an antibody
that binds the FGF23 in XLH patients normalizing the phosphorus levels
and improving the bone mineralization[15].
International data shows that early diagnosis and improved treat
ment for a number of bone disorders have increased the number of
children who survive to adulthood with improved quality of life. Genetic
counseling is also important step for individuals and families following
the diagnosis to help them better understand the disorder, consider their
options, and plan for the future. Family members may be advised about
their options to be tested. Lack of availability and access to genetic
counsellors in Pakistan is one negelcted area. There is a need to educate
and assist physicians about the rare bone diseases in Pakistan for
improving the provision of care. Need for development of local clinical
practice guidelines, continuing medical education activities, develop
ment of centers of excellence for rare skeletal disease and/or establish
ing referral centers is needed in a resource limite country like Pakistan.
The centers of excellence can also provide a base for research and may
act as nidus for establishment of a network of accredited care centers to
promote multidisciplinary, multicenter, collaborative research and
more resources for translational research. In addition, centers can bring
together comprehensive expertise and resources to address patient
needs, and to monitor the care provided to the patient suffering from
rare skeletal disorders.
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